BRPI1101627A2 - Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso - Google Patents

Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso Download PDF

Info

Publication number: BRPI1101627A2
Authority: BR; Brazil
Prior art keywords: films; volatile; controlled release; chitosan; film
Prior art date: 2011-04-15

Application number

BRPI1101627-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Augusto Gomes Faraco André

Gomes Ribeiro Tatiana

Oliveira Castilho Rachel

Original Assignee

Universidade Federal De Minas Gerais

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-15

Filing date

2011-04-15

Publication date

2018-07-31

2011-04-15 Application filed by Universidade Federal De Minas Gerais filed Critical Universidade Federal De Minas Gerais

2011-04-15 Priority to BRPI1101627-2A priority Critical patent/BRPI1101627A2/pt

2012-04-12 Priority to BR102012008550-0A priority patent/BR102012008550B1/pt

2012-04-13 Priority to PCT/BR2012/000111 priority patent/WO2012139190A1/fr

2018-07-31 Publication of BRPI1101627A2 publication Critical patent/BRPI1101627A2/pt

Links

239000000126 substance Substances 0.000 title claims abstract description 26
239000007787 solid Substances 0.000 title claims abstract description 23
238000013270 controlled release Methods 0.000 claims abstract description 24
229920000642 polymer Polymers 0.000 claims abstract description 23
230000002514 anti-leishmanial effect Effects 0.000 claims abstract description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 120
229940079593 drug Drugs 0.000 claims description 65
239000003814 drug Substances 0.000 claims description 65
229920001661 Chitosan Polymers 0.000 claims description 57
239000010410 layer Substances 0.000 claims description 49
239000000243 solution Substances 0.000 claims description 46
229920002472 Starch Polymers 0.000 claims description 44
239000008107 starch Substances 0.000 claims description 44
235000019698 starch Nutrition 0.000 claims description 43
239000000203 mixture Substances 0.000 claims description 31
238000000034 method Methods 0.000 claims description 25
230000008569 process Effects 0.000 claims description 18
239000000454 talc Substances 0.000 claims description 17
229910052623 talc Inorganic materials 0.000 claims description 17
239000002356 single layer Substances 0.000 claims description 14
239000006185 dispersion Substances 0.000 claims description 11
238000000338 in vitro Methods 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
238000003381 deacetylation reaction Methods 0.000 claims description 3
230000000724 leishmaniacidal effect Effects 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
230000006196 deacetylation Effects 0.000 claims description 2
239000000341 volatile oil Substances 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims 3
239000000725 suspension Substances 0.000 claims 3
230000008021 deposition Effects 0.000 claims 2
239000004815 dispersion polymer Substances 0.000 claims 2
208000004554 Leishmaniasis Diseases 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
239000007864 aqueous solution Substances 0.000 claims 1
230000002500 effect on skin Effects 0.000 claims 1
238000000265 homogenisation Methods 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
235000005985 organic acids Nutrition 0.000 claims 1
229920006254 polymer film Polymers 0.000 claims 1
238000001179 sorption measurement Methods 0.000 claims 1
239000003039 volatile agent Substances 0.000 claims 1
229920005615 natural polymer Polymers 0.000 abstract description 9
239000007788 liquid Substances 0.000 abstract description 8
229920002988 biodegradable polymer Polymers 0.000 abstract description 7
239000004621 biodegradable polymer Substances 0.000 abstract description 7
239000010408 film Substances 0.000 description 107
FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 50
WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 50
FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 44
239000011159 matrix material Substances 0.000 description 20
238000009472 formulation Methods 0.000 description 18
238000012377 drug delivery Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
230000002035 prolonged effect Effects 0.000 description 10
230000000694 effects Effects 0.000 description 9
230000036571 hydration Effects 0.000 description 9
238000006703 hydration reaction Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 7
238000013265 extended release Methods 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 6
238000012512 characterization method Methods 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
244000045947 parasite Species 0.000 description 4
229920002807 Thiomer Polymers 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
239000012620 biological material Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000010409 thin film Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229920002101 Chitin Polymers 0.000 description 2
241000222724 Leishmania amazonensis Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000000919 ceramic Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
244000096108 cunha Species 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
-1 in. Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000001878 scanning electron micrograph Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000010200 validation analysis Methods 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
229920005682 EO-PO block copolymer Polymers 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
235000014020 Hymenaea courbaril Nutrition 0.000 description 1
240000008375 Hymenaea courbaril Species 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
229920002000 Xyloglucan Polymers 0.000 description 1
LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000005422 blasting Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
239000002440 industrial waste Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
102220240796 rs553605556 Human genes 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000000807 solvent casting Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000002352 surface water Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1101627-2A 2011-04-15 2011-04-15 Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso BRPI1101627A2 (pt)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
BRPI1101627-2A BRPI1101627A2 (pt)	2011-04-15	2011-04-15	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso
BR102012008550-0A BR102012008550B1 (pt)	2011-04-15	2012-04-12	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso
PCT/BR2012/000111 WO2012139190A1 (fr)	2011-04-15	2012-04-13	Films multicouches à libération contrôlée de substances volatiles adsorbées sur un support solide, et leur utilisation

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
BRPI1101627-2A BRPI1101627A2 (pt)	2011-04-15	2011-04-15	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso

Publications (1)

Publication Number	Publication Date
BRPI1101627A2 true BRPI1101627A2 (pt)	2018-07-31

Family

ID=47008726

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI1101627-2A BRPI1101627A2 (pt)	2011-04-15	2011-04-15	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso
BR102012008550-0A BR102012008550B1 (pt)	2011-04-15	2012-04-12	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR102012008550-0A BR102012008550B1 (pt)	2011-04-15	2012-04-12	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso

Country Status (2)

Country	Link
BR (2)	BRPI1101627A2 (fr)
WO (1)	WO2012139190A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5386176B2 (ja) *	2006-12-21	2014-01-15	フロイント産業株式会社	キトサン溶液及び該溶液から形成されたキトサンコーティング製剤

2011
- 2011-04-15 BR BRPI1101627-2A patent/BRPI1101627A2/pt not_active Application Discontinuation
2012
- 2012-04-12 BR BR102012008550-0A patent/BR102012008550B1/pt active IP Right Grant
- 2012-04-13 WO PCT/BR2012/000111 patent/WO2012139190A1/fr not_active Ceased

Also Published As

Publication number	Publication date
BR102012008550B1 (pt)	2022-04-19
WO2012139190A1 (fr)	2012-10-18
BR102012008550A2 (pt)	2013-11-26

Legal Events

Date	Code	Title	Description
2016-02-23	B15G	Petition not considered as such [chapter 15.7 patent gazette]
2016-04-26	B12F	Other appeals [chapter 12.6 patent gazette]
2018-07-31	B03A	Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
2018-08-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-09-25	B08H	Application fees: decision cancelled [chapter 8.8 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2483 DE 07/08/2018 POR TER SIDO INDEVIDA.
2018-10-02	B03G	Publication of an application: publication cancelled [chapter 3.7 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 3.1 NA RPI NO 2482 DE 31/07/2018 POR TER SIDO INDEVIDA.
2018-10-23	B11K	Dismissal acc. art. 17, par 2 of ipl - pending earlier application (priority claim) definitively shelved	Free format text: PRIORIDADE INTERNA NO BR102012008550-0
2018-10-30	B03F	Publication of an application: publication of application definitely dismissed [chapter 3.6 patent gazette]

Publication	Publication Date	Title
RU2678433C2 (ru)	2019-01-29	Депо-составы гидрофобного активного ингредиента и способы их получения
US7901707B2 (en)	2011-03-08	Biodegradable biocompatible implant and method of manufacturing same
JP5752248B2 (ja)	2015-07-22	リン脂質デポー
JP5580815B2 (ja)	2014-08-27	経粘膜デリバリーシステム
CN103370055B (zh)	2015-06-24	缓释性脂质体组合物及其制造方法
JP2012148089A (ja)	2012-08-09	有機物質が含浸された多孔性半導体を含む複合材料
MXPA02010740A (es)	2003-03-10	Composicion farmaceutica similar al gel para la administracion subcutanea que comprende acidos bisfosfonicos o sus sales.
CA3018670A1 (fr)	2017-10-05	Gel viscoelastique de liraglutide concu pour une administration une fois par semaine ou une fois toutes les deux semaines
TW202320803A (zh)	2023-06-01	製備脂質體調配物之方法
BRPI1101627A2 (pt)	2018-07-31	Filmes multicamadas de liberação controlada de substâncias voláteis adsorvidas em um suporte sólido e uso
CN115843246B (zh)	2026-01-06	用于治疗血管瘤的方法和组合物
El Hashemy et al.	2024	Novel In Situ Gel for Molnupiravir-Loaded Niosomes: Design, In Vitro Characterization and In Vivo Evaluation‎
RU2622755C1 (ru)	2017-06-19	Средство с липосомами, содержащими изониазид
BRPI0803807B1 (pt)	2022-04-12	Filme multicamada de quitosana para liberação prolongada de dexametasona, e processo de preparo do filme
CN104306335B (zh)	2019-08-09	一种氟康唑柔性纳米脂质囊泡组合物及其应用
Agrawal et al.	2022	Formulation, evaluation, and in vitro drug diffusion of niosomal gel of selected drug
Al-Assady	2021	Evaluation of Loratadine Liposomal Gels for Transdermal Treatment
Munot et al.	2014	Development and evaluation of biodegradable microspheres embedded in in situ gel for controlled delivery of hydrophilic drug for treating oral infections: In vitro and in vivo studies
EP4695192A2 (fr)	2026-02-18	Composés analgésiques comprenant des particules chargées et procédé de fabrication associé
WO2012042072A1 (fr)	2012-04-05	Formulations topiques d'amphotéricine b et procédé d'obtention
WO2015100508A1 (fr)	2015-07-09	Dispositif sous-dermal pour le stockage et la libération continue d'un composé anticancéreux pour les chiens, contenu dans des nanoparticules et des microparticules de zéolites naturelles et dans un milieu huileux
BR102017011378B1 (pt)	2025-04-29	Método de obtenção de filmes lipídico-biopoliméricos nanoestruturados, filmes lipídico-biopoliméricos nanoestruturados e seu uso
BR102017011378A2 (pt)	2018-12-18	método de obtenção de filmes lipídico-biopoliméricos nanoestruturados, filmes lipídico-biopoliméricos nanoestruturados e seu uso.
CZ2006697A3 (cs)	2008-05-21	Kompozice depotních olanzapinových injekcních systému
SG177788A1 (en)	2012-02-28	Transdermal pharmaceutical formulations